JP2008514611A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008514611A5 JP2008514611A5 JP2007533604A JP2007533604A JP2008514611A5 JP 2008514611 A5 JP2008514611 A5 JP 2008514611A5 JP 2007533604 A JP2007533604 A JP 2007533604A JP 2007533604 A JP2007533604 A JP 2007533604A JP 2008514611 A5 JP2008514611 A5 JP 2008514611A5
- Authority
- JP
- Japan
- Prior art keywords
- carbon atoms
- tetrahydro
- carboxylic acid
- cyclopenta
- indole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000004432 carbon atom Chemical group C* 0.000 claims 120
- 125000000217 alkyl group Chemical group 0.000 claims 36
- -1 furanylmethyl Chemical group 0.000 claims 33
- 125000001072 heteroaryl group Chemical group 0.000 claims 18
- 125000003342 alkenyl group Chemical group 0.000 claims 15
- 125000003710 aryl alkyl group Chemical group 0.000 claims 15
- 125000003118 aryl group Chemical group 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 12
- 125000002877 alkyl aryl group Chemical group 0.000 claims 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims 12
- 238000000034 method Methods 0.000 claims 12
- 125000003107 substituted aryl group Chemical group 0.000 claims 12
- 125000000304 alkynyl group Chemical group 0.000 claims 9
- 229910052799 carbon Inorganic materials 0.000 claims 9
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 6
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 5
- AFDTUDKFSMWIAU-UHFFFAOYSA-N 2-(5,7-difluoro-1-propyl-2,3,4,9-tetrahydrocarbazol-1-yl)acetic acid Chemical compound N1C2=CC(F)=CC(F)=C2C2=C1C(CCC)(CC(O)=O)CCC2 AFDTUDKFSMWIAU-UHFFFAOYSA-N 0.000 claims 3
- KKRITWOLVWDFFN-UHFFFAOYSA-N 2-(5,8-dicyano-1-propyl-2,3,4,9-tetrahydrocarbazol-1-yl)acetic acid Chemical compound N1C2=C(C#N)C=CC(C#N)=C2C2=C1C(CCC)(CC(O)=O)CCC2 KKRITWOLVWDFFN-UHFFFAOYSA-N 0.000 claims 3
- NQNDJICKBDRTND-UHFFFAOYSA-N 2-(5-cyano-8-fluoro-1-propyl-2,3,4,9-tetrahydrocarbazol-1-yl)acetic acid Chemical compound N1C2=C(F)C=CC(C#N)=C2C2=C1C(CCC)(CC(O)=O)CCC2 NQNDJICKBDRTND-UHFFFAOYSA-N 0.000 claims 3
- SGWDODVGBXFOHX-UHFFFAOYSA-N 2-(8-carbamoyl-5-cyano-1-propyl-2,3,4,9-tetrahydrocarbazol-1-yl)acetic acid Chemical compound N1C2=C(C(N)=O)C=CC(C#N)=C2C2=C1C(CCC)(CC(O)=O)CCC2 SGWDODVGBXFOHX-UHFFFAOYSA-N 0.000 claims 3
- NDKUXQXILLYKKZ-UHFFFAOYSA-N 3-butyl-5,8-dichloro-2,4-dihydro-1h-cyclopenta[b]indole-3-carboxylic acid Chemical compound N1C2=C(Cl)C=CC(Cl)=C2C2=C1C(CCCC)(C(O)=O)CC2 NDKUXQXILLYKKZ-UHFFFAOYSA-N 0.000 claims 3
- VUCHCGKNUOLUQK-UHFFFAOYSA-N 3-butyl-7-fluoro-5-methyl-2,4-dihydro-1h-cyclopenta[b]indole-3-carboxylic acid Chemical compound N1C2=C(C)C=C(F)C=C2C2=C1C(CCCC)(C(O)=O)CC2 VUCHCGKNUOLUQK-UHFFFAOYSA-N 0.000 claims 3
- ROLZHTZWLHLZCQ-UHFFFAOYSA-N 3-butyl-8-cyano-5-fluoro-2,4-dihydro-1h-cyclopenta[b]indole-3-carboxylic acid Chemical compound N1C2=C(F)C=CC(C#N)=C2C2=C1C(CCCC)(C(O)=O)CC2 ROLZHTZWLHLZCQ-UHFFFAOYSA-N 0.000 claims 3
- VQOPOVBNNLJNSI-UHFFFAOYSA-N 3-butyl-8-cyano-5-methyl-2,4-dihydro-1h-cyclopenta[b]indole-3-carboxylic acid Chemical compound N1C2=C(C)C=CC(C#N)=C2C2=C1C(CCCC)(C(O)=O)CC2 VQOPOVBNNLJNSI-UHFFFAOYSA-N 0.000 claims 3
- PJCITKIXTABVGF-UHFFFAOYSA-N 3-butyl-8-cyano-7-fluoro-5-methyl-2,4-dihydro-1h-cyclopenta[b]indole-3-carboxylic acid Chemical compound N1C2=C(C)C=C(F)C(C#N)=C2C2=C1C(CCCC)(C(O)=O)CC2 PJCITKIXTABVGF-UHFFFAOYSA-N 0.000 claims 3
- TVSMABGYTPMGPU-UHFFFAOYSA-N 5,8-dichloro-1-ethyl-2,3,4,9-tetrahydrocarbazole-1-carboxylic acid Chemical compound N1C2=C(Cl)C=CC(Cl)=C2C2=C1C(CC)(C(O)=O)CCC2 TVSMABGYTPMGPU-UHFFFAOYSA-N 0.000 claims 3
- WXVDJFVBOHMICQ-UHFFFAOYSA-N 5,8-dichloro-1-propyl-2,3,4,9-tetrahydrocarbazole-1-carboxylic acid Chemical compound N1C2=C(Cl)C=CC(Cl)=C2C2=C1C(CCC)(C(O)=O)CCC2 WXVDJFVBOHMICQ-UHFFFAOYSA-N 0.000 claims 3
- UVKVBHPKFLJUCF-UHFFFAOYSA-N 5,8-dichloro-3-prop-2-enyl-2,4-dihydro-1h-cyclopenta[b]indole-3-carboxylic acid Chemical compound N1C2=C(Cl)C=CC(Cl)=C2C2=C1C(C(=O)O)(CC=C)CC2 UVKVBHPKFLJUCF-UHFFFAOYSA-N 0.000 claims 3
- ZEBPOFKSMDBBIP-UHFFFAOYSA-N 5,8-dichloro-3-propyl-2,4-dihydro-1h-cyclopenta[b]indole-3-carboxylic acid Chemical compound N1C2=C(Cl)C=CC(Cl)=C2C2=C1C(CCC)(C(O)=O)CC2 ZEBPOFKSMDBBIP-UHFFFAOYSA-N 0.000 claims 3
- BGJZMLAKAFRASM-UHFFFAOYSA-N 5-cyano-1-(cyclobutylmethyl)-8-fluoro-2,3,4,9-tetrahydrocarbazole-1-carboxylic acid Chemical compound C1CCC(C2=C(C#N)C=CC(F)=C2N2)=C2C1(C(=O)O)CC1CCC1 BGJZMLAKAFRASM-UHFFFAOYSA-N 0.000 claims 3
- KRFGICBRUITTJH-UHFFFAOYSA-N 5-cyano-8-fluoro-1-propyl-2,3,4,9-tetrahydrocarbazole-1-carboxylic acid Chemical compound N1C2=C(F)C=CC(C#N)=C2C2=C1C(CCC)(C(O)=O)CCC2 KRFGICBRUITTJH-UHFFFAOYSA-N 0.000 claims 3
- MODPSKZFBZNESH-UHFFFAOYSA-N 5-cyano-8-methyl-1-propyl-2,3,4,9-tetrahydrocarbazole-1-carboxylic acid Chemical compound N1C2=C(C)C=CC(C#N)=C2C2=C1C(CCC)(C(O)=O)CCC2 MODPSKZFBZNESH-UHFFFAOYSA-N 0.000 claims 3
- GGMQIOLVDVZJEY-UHFFFAOYSA-N 8-bromo-3-butyl-5-fluoro-2,4-dihydro-1h-cyclopenta[b]indole-3-carboxylic acid Chemical compound N1C2=C(F)C=CC(Br)=C2C2=C1C(CCCC)(C(O)=O)CC2 GGMQIOLVDVZJEY-UHFFFAOYSA-N 0.000 claims 3
- BELKQACUXXVKGU-UHFFFAOYSA-N 8-bromo-3-butyl-5-methyl-2,4-dihydro-1h-cyclopenta[b]indole-3-carboxylic acid Chemical compound N1C2=C(C)C=CC(Br)=C2C2=C1C(CCCC)(C(O)=O)CC2 BELKQACUXXVKGU-UHFFFAOYSA-N 0.000 claims 3
- PJSPQZHMSYHQHW-UHFFFAOYSA-N 8-bromo-3-butyl-7-fluoro-5-methyl-2,4-dihydro-1h-cyclopenta[b]indole-3-carboxylic acid Chemical compound N1C2=C(C)C=C(F)C(Br)=C2C2=C1C(CCCC)(C(O)=O)CC2 PJSPQZHMSYHQHW-UHFFFAOYSA-N 0.000 claims 3
- AVGMUKWZKNEEGD-UHFFFAOYSA-N 8-bromo-5-fluoro-3-propyl-2,4-dihydro-1h-cyclopenta[b]indole-3-carboxylic acid Chemical compound N1C2=C(F)C=CC(Br)=C2C2=C1C(CCC)(C(O)=O)CC2 AVGMUKWZKNEEGD-UHFFFAOYSA-N 0.000 claims 3
- YTYSTPUXYCVFKA-UHFFFAOYSA-N 8-bromo-5-methyl-3-propyl-2,4-dihydro-1h-cyclopenta[b]indole-3-carboxylic acid Chemical compound N1C2=C(C)C=CC(Br)=C2C2=C1C(CCC)(C(O)=O)CC2 YTYSTPUXYCVFKA-UHFFFAOYSA-N 0.000 claims 3
- SOOIMQWGGBSTMX-UHFFFAOYSA-N 8-bromo-7-fluoro-5-methyl-3-propyl-2,4-dihydro-1h-cyclopenta[b]indole-3-carboxylic acid Chemical compound N1C2=C(C)C=C(F)C(Br)=C2C2=C1C(CCC)(C(O)=O)CC2 SOOIMQWGGBSTMX-UHFFFAOYSA-N 0.000 claims 3
- UJIFIPSJPHVBSG-UHFFFAOYSA-N 8-chloro-1-propyl-5-(trifluoromethyl)-2,3,4,9-tetrahydrocarbazole-1-carboxylic acid Chemical compound N1C2=C(Cl)C=CC(C(F)(F)F)=C2C2=C1C(CCC)(C(O)=O)CCC2 UJIFIPSJPHVBSG-UHFFFAOYSA-N 0.000 claims 3
- GBRSGCDWLVKGNZ-UHFFFAOYSA-N 8-cyano-5-fluoro-3-prop-2-enyl-2,4-dihydro-1h-cyclopenta[b]indole-3-carboxylic acid Chemical compound N1C2=C(F)C=CC(C#N)=C2C2=C1C(C(=O)O)(CC=C)CC2 GBRSGCDWLVKGNZ-UHFFFAOYSA-N 0.000 claims 3
- CYFCIXPSJVHSMX-UHFFFAOYSA-N 8-cyano-5-fluoro-3-propyl-2,4-dihydro-1h-cyclopenta[b]indole-3-carboxylic acid Chemical compound N1C2=C(F)C=CC(C#N)=C2C2=C1C(CCC)(C(O)=O)CC2 CYFCIXPSJVHSMX-UHFFFAOYSA-N 0.000 claims 3
- VYYVCKMHOOZGSL-UHFFFAOYSA-N 8-cyano-5-methyl-3-prop-2-enyl-2,4-dihydro-1h-cyclopenta[b]indole-3-carboxylic acid Chemical compound CC1=CC=C(C#N)C2=C1NC1=C2CCC1(C(O)=O)CC=C VYYVCKMHOOZGSL-UHFFFAOYSA-N 0.000 claims 3
- GXCUYACJTXNSGX-UHFFFAOYSA-N 8-cyano-5-methyl-3-propyl-2,4-dihydro-1h-cyclopenta[b]indole-3-carboxylic acid Chemical compound N1C2=C(C)C=CC(C#N)=C2C2=C1C(CCC)(C(O)=O)CC2 GXCUYACJTXNSGX-UHFFFAOYSA-N 0.000 claims 3
- YBEFUBSZGDRNEE-UHFFFAOYSA-N 8-cyano-7-fluoro-5-methyl-3-prop-2-enyl-2,4-dihydro-1h-cyclopenta[b]indole-3-carboxylic acid Chemical compound CC1=CC(F)=C(C#N)C2=C1NC1=C2CCC1(C(O)=O)CC=C YBEFUBSZGDRNEE-UHFFFAOYSA-N 0.000 claims 3
- NNMAGWLGRCCEIE-UHFFFAOYSA-N 8-cyano-7-fluoro-5-methyl-3-propyl-2,4-dihydro-1h-cyclopenta[b]indole-3-carboxylic acid Chemical compound N1C2=C(C)C=C(F)C(C#N)=C2C2=C1C(CCC)(C(O)=O)CC2 NNMAGWLGRCCEIE-UHFFFAOYSA-N 0.000 claims 3
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 3
- 125000006350 alkyl thio alkyl group Chemical group 0.000 claims 3
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 3
- 125000004966 cyanoalkyl group Chemical group 0.000 claims 3
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000001984 thiazolidinyl group Chemical group 0.000 claims 3
- 208000005176 Hepatitis C Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims 1
- 101800001554 RNA-directed RNA polymerase Proteins 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 208000010710 hepatitis C virus infection Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61214404P | 2004-09-23 | 2004-09-23 | |
| PCT/US2005/033803 WO2006034337A2 (en) | 2004-09-23 | 2005-09-21 | Carbazole and cyclopentaindole derivatives to treat infection with hepatitis c virus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008514611A JP2008514611A (ja) | 2008-05-08 |
| JP2008514611A5 true JP2008514611A5 (enExample) | 2008-11-06 |
Family
ID=35907017
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007533604A Withdrawn JP2008514611A (ja) | 2004-09-23 | 2005-09-21 | Ｃ型肝炎ウイルスによる感染を処置するためのカルバゾールおよびシクロペンタインドールの誘導体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7250441B2 (enExample) |
| EP (1) | EP1793819A2 (enExample) |
| JP (1) | JP2008514611A (enExample) |
| CN (1) | CN101035528A (enExample) |
| AU (1) | AU2005286727A1 (enExample) |
| BR (1) | BRPI0515596A (enExample) |
| CA (1) | CA2577413A1 (enExample) |
| MX (1) | MX2007003371A (enExample) |
| WO (1) | WO2006034337A2 (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006121467A2 (en) * | 2004-11-22 | 2006-11-16 | Smithkline Beecham Corporation | Tetrahydrocarbazole derivatives for treating flaviridae viruses |
| AU2006292337B8 (en) | 2005-09-19 | 2013-02-07 | Emisphere Technologies, Inc. | Crystalline forms of the di-sodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid |
| AU2007286754A1 (en) * | 2006-08-25 | 2008-02-28 | Viropharma Incorporated | Identification and characterization of HCV replicon variants with reduced susceptibility to HCV-796, and methods related thereto |
| US8546420B2 (en) | 2006-12-22 | 2013-10-01 | Merck Sharp & Dohme Corp. | 4, 5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections |
| WO2008136815A2 (en) | 2006-12-22 | 2008-11-13 | Schering Corporation | 5, 6-ring annulated indole derivatives and use thereof |
| BRPI0720625A2 (pt) | 2006-12-22 | 2014-03-25 | Schering Corp | Derivados de indol de 4,5-anel anulados e métodos de uso dos mesmos |
| EP2494991A1 (en) | 2007-05-04 | 2012-09-05 | Vertex Pharmaceuticals Incorporated | Combination therapy for the treatment of HCV infection |
| TW200918536A (en) * | 2007-08-29 | 2009-05-01 | Schering Corp | Tetracyclic indole derivatives and methods of use thereof |
| CA2697454C (en) | 2007-08-29 | 2015-11-03 | Schering Corporation | 2-carboxy substituted indole derivatives and methods of use thereof |
| RU2010111550A (ru) | 2007-08-29 | 2011-10-10 | Шеринг Корпорейшн (US) | 2,3-замещенные индольные производные для лечения вирусных инфекций |
| JP5258889B2 (ja) | 2007-08-29 | 2013-08-07 | メルク・シャープ・アンド・ドーム・コーポレーション | ウイルス感染症の治療のための２，３−置換アザインドール誘導体 |
| AU2008309589B2 (en) * | 2007-10-10 | 2012-07-05 | Novartis Ag | Spiropyrrolidines and their use against HCV and HIV infection |
| MX2010005356A (es) | 2007-11-16 | 2010-05-27 | Schering Corp | Derivados de indol 3-heterociclico sustituidos y metodos de uso de los mismos. |
| EP2222672B1 (en) | 2007-11-16 | 2013-12-18 | Merck Sharp & Dohme Corp. | 3-aminosulfonyl substituted indole derivatives and methods of use thereof |
| JP5580814B2 (ja) | 2008-06-13 | 2014-08-27 | メルク・シャープ・アンド・ドーム・コーポレーション | ３環式インドール誘導体およびその使用方法 |
| KR20190004843A (ko) * | 2008-07-23 | 2019-01-14 | 아레나 파마슈티칼스, 인크. | 자가면역성 및 염증성의 장애의 치료에 유용한 치환된 1,2,3,4-테트라히드로시클로펜타[ｂ]인돌-3-일)아세트산 유도체 |
| JP5726737B2 (ja) * | 2008-08-27 | 2015-06-03 | アリーナ ファーマシューティカルズ， インコーポレイテッド | 自己免疫障害および免疫性障害の治療において有用なｓ１ｐ１受容体のアゴニストとしての置換三環式酸誘導体 |
| BRPI0922565A2 (pt) | 2008-12-19 | 2015-12-15 | Bristol Myers Squibb Co | compostos de carbazol carboxamida úteis como inibidores de cinase |
| CN108558740B (zh) | 2010-01-27 | 2021-10-19 | 艾尼纳制药公司 | S1p1受体调节剂及其盐的制备方法 |
| CA2789480A1 (en) | 2010-03-03 | 2011-09-09 | Arena Pharmaceuticals, Inc. | Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof |
| CN105566202B (zh) * | 2014-10-31 | 2018-06-22 | 华东师范大学 | 一种1，2，3，4-四氢环戊基吲哚衍生物及其合成方法 |
| PL3242666T3 (pl) | 2015-01-06 | 2025-02-17 | Arena Pharmaceuticals, Inc. | Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1 |
| HUE060476T2 (hu) | 2015-06-22 | 2023-03-28 | Arena Pharm Inc | (R)-2-(7-(4-ciklopentil-3-(trifluormetil)benziloxi)-1,2,3,4- tetrahidrociklopenta[B]indol-3-il)ecetsav kristályos L-arginin-sója S1P1 receptorral kapcsolatos rendellenességek esetén való alkalmazásra |
| US20170107216A1 (en) | 2015-10-19 | 2017-04-20 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| AU2016358100B2 (en) | 2015-11-19 | 2021-05-27 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| TW201726623A (zh) | 2015-12-17 | 2017-08-01 | 英塞特公司 | 作為免疫調節劑之雜環化合物 |
| TWI850624B (zh) | 2015-12-22 | 2024-08-01 | 美商英塞特公司 | 作為免疫調節劑之雜環化合物 |
| TW201808950A (zh) | 2016-05-06 | 2018-03-16 | 英塞特公司 | 作為免疫調節劑之雜環化合物 |
| US20170342060A1 (en) | 2016-05-26 | 2017-11-30 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| DK3472167T3 (da) | 2016-06-20 | 2022-09-05 | Incyte Corp | Heterocykliske forbindelser som immunomodulatorer |
| EP3484866B1 (en) | 2016-07-14 | 2022-09-07 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| EP3504198B1 (en) | 2016-08-29 | 2023-01-25 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| EP3558963B1 (en) | 2016-12-22 | 2022-03-23 | Incyte Corporation | Bicyclic heteroaromatic compounds as immunomodulators |
| EP3558973B1 (en) | 2016-12-22 | 2021-09-15 | Incyte Corporation | Pyridine derivatives as immunomodulators |
| ES2874756T3 (es) | 2016-12-22 | 2021-11-05 | Incyte Corp | Derivados de triazolo[1,5-A]piridina como inmunomoduladores |
| IL295660A (en) | 2016-12-22 | 2022-10-01 | Incyte Corp | Benzooxazole derivatives as immunomodulators |
| WO2018151873A1 (en) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
| CN110545848A (zh) | 2017-02-16 | 2019-12-06 | 艾尼纳制药公司 | 用于治疗具有肠外表现的炎症性肠病的化合物和方法 |
| RS64055B1 (sr) | 2018-03-30 | 2023-04-28 | Incyte Corp | Heterociklična jedinjenja kao imunomodulatori |
| EP4219492B1 (en) | 2018-05-11 | 2024-11-27 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| US12156866B2 (en) | 2018-06-06 | 2024-12-03 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
| EP3847158A1 (en) | 2018-09-06 | 2021-07-14 | Arena Pharmaceuticals, Inc. | Compounds useful in the treatment of autoimmune and inflammatory disorders |
| JP7665593B2 (ja) | 2019-08-09 | 2025-04-21 | インサイト・コーポレイション | Ｐｄ－１／ｐｄ－ｌ１阻害剤の塩 |
| EP4037773A1 (en) | 2019-09-30 | 2022-08-10 | Incyte Corporation | Pyrido[3,2-d]pyrimidine compounds as immunomodulators |
| BR112022009031A2 (pt) | 2019-11-11 | 2022-10-11 | Incyte Corp | Sais e formas cristalinas de um inibidor de pd-1/pd-l1 |
| WO2022099018A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Process of preparing a pd-1/pd-l1 inhibitor |
| EP4240739A1 (en) | 2020-11-06 | 2023-09-13 | Incyte Corporation | Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof |
| US11760756B2 (en) | 2020-11-06 | 2023-09-19 | Incyte Corporation | Crystalline form of a PD-1/PD-L1 inhibitor |
| CN116854622A (zh) * | 2023-07-10 | 2023-10-10 | 青岛科技大学 | 一种多取代的2,4-二氢环戊二烯并[b]吲哚类化合物的合成方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0307077A1 (en) | 1987-07-21 | 1989-03-15 | Merck Frosst Canada Inc. | Tetrahydrocarbazoles for the improvement of cyclosporin therapy |
| US5830911A (en) * | 1996-08-14 | 1998-11-03 | American Home Products Corporation | Pyranoindole and tetrahydrocarbazole inhibitors of COX-2 |
| JP4126345B2 (ja) | 1997-03-06 | 2008-07-30 | 松森 昭 | ウイルス感染症の予防・治療剤 |
| US20050256181A1 (en) | 2004-01-29 | 2005-11-17 | Elixir Pharmaceuticals, Inc. | Treating a viral disorder |
-
2005
- 2005-09-21 CA CA002577413A patent/CA2577413A1/en not_active Abandoned
- 2005-09-21 AU AU2005286727A patent/AU2005286727A1/en not_active Abandoned
- 2005-09-21 EP EP05815334A patent/EP1793819A2/en not_active Withdrawn
- 2005-09-21 WO PCT/US2005/033803 patent/WO2006034337A2/en not_active Ceased
- 2005-09-21 US US11/230,729 patent/US7250441B2/en not_active Expired - Fee Related
- 2005-09-21 BR BRPI0515596-7A patent/BRPI0515596A/pt not_active IP Right Cessation
- 2005-09-21 JP JP2007533604A patent/JP2008514611A/ja not_active Withdrawn
- 2005-09-21 CN CNA2005800316732A patent/CN101035528A/zh active Pending
- 2005-09-21 MX MX2007003371A patent/MX2007003371A/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008514611A5 (enExample) | ||
| DE60224401T2 (de) | Hepatitis c virus polymerase inhibitoren mit heterobicylischer struktur | |
| JP2011519910A5 (enExample) | ||
| JP2008513498A5 (enExample) | ||
| JP2009524676A5 (enExample) | ||
| JP2004516314A5 (enExample) | ||
| JP2010529147A5 (enExample) | ||
| JP2008501000A5 (enExample) | ||
| JP2007511615A5 (enExample) | ||
| JP2005053931A5 (enExample) | ||
| JP2011524422A5 (enExample) | ||
| JP2005533040A5 (enExample) | ||
| JP2010504908A5 (enExample) | ||
| JP2007535491A5 (enExample) | ||
| JP2010500293A5 (enExample) | ||
| JP2008514611A (ja) | Ｃ型肝炎ウイルスによる感染を処置するためのカルバゾールおよびシクロペンタインドールの誘導体 | |
| JP2007501809A5 (enExample) | ||
| JP2006515364A (ja) | ウイルスポリメラーゼ抑制剤 | |
| JP2009504763A5 (enExample) | ||
| JP2006507220A5 (enExample) | ||
| JP2004535466A5 (enExample) | ||
| JP2021073250A5 (enExample) | ||
| JP2010521471A5 (enExample) | ||
| WO2003099801A1 (en) | Novel anti-infectives | |
| JP2005511594A5 (enExample) |